BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20131304)

  • 21. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes.
    Wang H; Wang X; Xu X; Lin G
    Ann Hematol; 2010 Jul; 89(7):671-9. PubMed ID: 20179929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
    Br J Haematol; 2012 May; 157(3):321-30. PubMed ID: 22360654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
    Porrata LF; Ingle JN; Litzow MR; Geyer S; Markovic SN
    Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.
    Sun D; Elson P; Liedtke M; Medeiros BC; Earl M; Alizadeh A; Bates J; Sekeres MA; Coutre S; Kalaycio M; Sobecks R; Copelan E; Advani AS
    Am J Hematol; 2012 Oct; 87(10):957-60. PubMed ID: 22729847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
    Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
    Wimazal F; Germing U; Kundi M; Noesslinger T; Blum S; Geissler P; Baumgartner C; Pfeilstoecker M; Valent P; Sperr WR
    Cancer; 2010 May; 116(10):2372-81. PubMed ID: 20209617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.
    Kim H; Sohn HJ; Kim SE; Kang HJ; Park S; Kim S; Kim WK; Lee JS; Suh C
    Bone Marrow Transplant; 2004 Jul; 34(1):43-9. PubMed ID: 15107814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
    De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
    Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients.
    Saeed L; Patnaik MM; Begna KH; Al-Kali A; Litzow MR; Hanson CA; Ketterling RP; Porrata LF; Pardanani A; Gangat N; Tefferi A
    Blood Cancer J; 2017 Mar; 7(3):e550. PubMed ID: 28362440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Giardini I; Rocca B; Zappatore R; Dambruoso I; Calvello C; Caresana M; Lazzarino M
    Ann Hematol; 2010 Jun; 89(6):545-51. PubMed ID: 20217086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution.
    Balduini CL; Guarnone R; Pecci A; Centenara E; Invernizzi R; Ascari E
    Haematologica; 1999 Jan; 84(1):12-6. PubMed ID: 10091387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.